Ellen de Kort

27 Sedation for the INSURE procedure 2 Definition of intubation conditions Definition of INSURE failure Predefined side effects Not defined FiO 2 > 0.40 on nCPAP, intractable apnea (>4 episodes of apnea/hour or >2 episodes of apnea/hour requiring bag and mask ventilation) or severe respiratory acidosis (pH <7.12 and pCO 2 >70 mmHg) within 7 days from extubation Not defined Not defined Not defined Not defined Not defined Need for MV in first week after surfactant treatment. Need for MV: PaCO 2 ≥8.5 kPa, FiO 2 ≥0.60, signs of severe respiratory distress or apnea Not defined Not defined Need for MV during 24 hours after surfactant treatment. Criteria for MV: >3 episodes of apnea per 3 hours irresponsive of stimulation and caffeine treatment, arterial pH <7.20, arterial pCO 2 >65 mmHg, a/ApO 2 <0.15, metabolic acidosis not responsive to treatment Not defined Not defined FiO 2 >0.40 to maintain SpO 2 85-95%, significant apnea defined as >4 episodes of apnea/hour or >2 apnea/hour requiring bag and mask ventilation, respiratory acidosis pCO 2 >65 mmHg and pH <7.20) Not reported Not defined Not defined Not defined Need for MV during admission to the NICU. Criteria for MV: PaCO 2 ≥8.5 kPa, FiO 2 ≥0.60, signs of severe respiratory distress or apnea Need for MV during first week. Criteria: FiO 2 >0.40 for SpO 2 85-93%, significant apnea (>4 apnea/hour or >2 apnea/ hour requiring bag and mask ventilation), respiratory acidosis (pCO 2 >65 mmHg, pH <7.20), FiO 2 rapidly increasing >0.80